Skip to main content

Ainnocence

Category: AI in Healthcare

A generative AI-driven biotech platform that utilizes self-evolving algorithms to accelerate the discovery and design of therapeutics, gene therapies, and cosmetic formulations. Ainnocence was founded in 2021. The company is led by Lurong Pan. Based in Birmingham, USA. Team size: 11-50. Total funding raised: $3.62M. Latest round: Equity Crowdfunding. Key investors include ["Genesis Capital","Iaso Ventures","StartEngine","Alabama Launchpad"].

Founded
2021
Headquarters
Birmingham, USA
Team size
11-50
Total funding
$3.62M

Value proposition

Reduces R&D timelines from years to weeks by screening up to 10^10 molecular sequences in hours, enabling multi-objective optimization of efficacy, safety, and manufacturability simultaneously.

Products and solutions

["SentinusAI® (De novo antibody and protein engineering engine)","CarbonAI® (Small-molecule and PROTAC design platform)","CellulaAI™ (Cell-therapy and vaccine optimization)","CosmeticAI™ (AI-driven skincare and beauty formulation tool)","AAV Design Services (Next-generation viral vector engineering for gene therapy)"]

Unique value

Employs a 'sequence-first' generative AI approach that designs molecules based solely on sequence data, bypassing the traditional requirement for high-resolution 3D structures to initiate discovery.

Target customer

Pharmaceutical and biotechnology companies, skincare and beauty brands, academic research institutions, and gene therapy developers.

Industries served

["Biotechnology","Pharmaceuticals","Cosmetics & Personal Care","Gene & Cell Therapy"]

Technology advantage

Features a 'self-evolving' engine that improves through reinforcement learning cycles; capable of 10,000x faster screening speeds than traditional methods while balancing multiple pharmacological objectives in a single workflow.

How they differentiate

Ainnocence utilizes a 'sequence-first' generative AI approach that bypasses the need for high-resolution 3D structures, enabling the screening of up to 10^10 sequences in hours. Unlike many biotech-only competitors, it has diversified into the beauty industry with its CosmeticAI™ platform for skincare formulation.

Main competitors

["Insilico Medicine","Absci","Schrödinger","Atomwise"]

Key partnerships

["Sino Biological (AI-enabled antibody affinity maturation)","Obatala Sciences (Integration of AI with human biological models)","Southern Research (Drug discovery and development collaboration)","Global Health Drug Discovery Institute (GHDDI)","Strategic collaborations with major entities including the Gates Foundation, Pfizer, and Bayer (as disclosed by leadership)"]

Notable customers

["Sino Biological","Obatala Sciences","Southern Research","Global Health Drug Discovery Institute (GHDDI)"]

Major milestones

["Winner of the Alabama Launchpad startup competition (2022)","Launched AAV design services for gene therapy (2024)","Successfully closed StartEngine crowdfunding campaign (2024)","Launched CosmeticAI™ for AI-driven skincare innovation (January 2025)"]

Growth metrics

Commercial-stage with active revenue-generating partnerships; expanded from drug discovery into a multi-vertical platform including gene therapy (AAV) and cosmetics.

Market positioning

Specialized AI-Biotech platform provider offering end-to-end molecular design for therapeutics, gene therapy, and cosmetics.

Geographic focus

North America (HQ in Alabama) and Asia-Pacific (strategic partnerships in China).

Patents and IP

Proprietary sequence-based AI scoring logic and generative models; SentinusAI®, CarbonAI®, and CellulaAI™ are registered trademarks with underlying proprietary IP.

About Lurong Pan

Over 15 years of expertise in computational drug design and AI. Previously served as a Senior Scientist at the Global Health Drug Discovery Institute (GHDDI) and a Research Scientist at Southern Research. Expert in generative AI for protein engineering and molecular design, with a PhD in Computational Chemistry/Biophysics from the University of Alabama at Birmingham.

Official website: